TEANECK, N.J., Feb. 17, 2012  /PRNewswire/ -- Cognizant (NASDAQ: CTSH), a leading provider of information technology, consulting, and business process outsourcing services, today announced that it has been selected by CentraState Healthcare System, a leading not-for-profit community health organization, to develop a strategy for transitioning to ICD-10. As part of the engagement, Cognizant will perform a comprehensive ICD-10 assessment to determine the clinical, administrative, and financial impact on business and IT processes, staff, and partners, and recommend an implementation strategy to enable a smooth transition to ICD-10 and meet the 2013 compliance deadline.

"This engagement will allow CentraState to leverage Cognizant's extensive domain, consulting, technology, and regulatory expertise to prepare for the transition to ICD-10," said Indranil Ganguly, Vice President and Chief Information Officer of CentraState. "Cognizant's end-to-end regulatory compliance capabilities and experience with multiple payer and provider organizations will help us plan our journey to ICD-10."

"We are pleased to have been selected by CentraState as a partner in this important strategic initiative," said Krish Venkat, Executive Vice President and Global Leader of Cognizant's Healthcare practice. "We look forward to working with CentraState to develop a compliance blueprint that will enable CentraState to improve care quality, optimize reimbursements, and increase physician and patient satisfaction by addressing the technical and operational implications of transition to ICD-10."

About CentraState Healthcare System

CentraState Healthcare System is a non-profit community health organization consisting of an acute-care hospital, an ambulatory care campus, three senior living communities, a Family Medicine Residency Program, and a charitable foundation. CentraState Medical Center is a member of the Robert Wood Johnson Health Network and a clinical research affiliate of The Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center. For more information, please visit www.centrastate.com.

About Cognizant's Healthcare and Life Sciences Practice

Cognizant's Healthcare and Life Sciences practice is committed to helping change millions of lives for the better by partnering with clients to build solutions to healthcare challenges, continually improve the way they do business, set the pace in clinical development, strengthen their regulatory infrastructure, and increase competitiveness. Consistently ranked among the top 10 on the Healthcare Informatics Top 100, Cognizant serves 27 of the top 30 global pharmaceutical companies, 15 of the top 20 health plans in the U.S., 5 of the top 6 pharmacy benefit management companies in the U.S., 9 of the top 10 biotech companies, and 12 of the top 20 medical device companies. With a large team of dedicated professionals including doctors, pharmacologists, physicians, biomedical engineers, pharmacists, biostatisticians, medical writers, and GxP consultants, the practice provides domain-aligned consulting, IT, business process and analytics solutions globally.

About Cognizant

Cognizant (NASDAQ: CTSH) is a leading provider of information technology, consulting, and business process outsourcing services, dedicated to helping the world's leading companies build stronger businesses. Headquartered in Teaneck, New Jersey (U.S.), Cognizant combines a passion for client satisfaction, technology innovation, deep industry and business process expertise, and a global, collaborative workforce that embodies the future of work. With over 50 delivery centers worldwide and approximately 137,700 employees as of December 31, 2011, Cognizant is a member of the NASDAQ-100, the S&P 500, the Forbes Global 2000, and the Fortune 500 and is ranked among the top performing and fastest growing companies in the world. Visit us online at www.cognizant.com or follow us on Twitter: Cognizant.

Forward-Looking Statements

This press release includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those expressed or implied include general economic conditions and the factors discussed in our most recent Form 10-K and other filings with the Securities and Exchange Commission. Cognizant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

SOURCE Cognizant